Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua’s Progress District
Concept Companies, a national commercial real estate developer specializing in turnkey projects, announces the commencement of the design and construction of a new 11,961-square-foot laboratory facility for Lacerta Therapeutics, Inc., a gene therapy company. The site will be located adjacent to Lacerta Therapeutics' current location in Alachua, Florida, in Copeland Park, which Lacerta has occupied since 2020.
Alcyone Presents Preclinical Data on Gene Therapy Programs With the Center for Gene Therapy at the Abigail Wexner Research Institute (AWRI) at ASGCT 2022
Sid Martin Client Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, presented preclinical data showing the Company's partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101 safely and effectively reactivates the inactive X chromosome in a Rett syndrome mouse model and is safe in a preliminary nonhuman primate study at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.
AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
CITI Program and Biotility at UF Announce Partnership
The Collaborative Institutional Training Initiative (CITI Program), the leader in online research, ethics, and compliance training, and Biotility at the University of Florida announced an exclusive licensing agreement to offer select Biotility’s biotech training courses on CITI Program’s learning platform.
BioFlorida Celebration of Biotechnology Shines a Light on the Future of the City of Alachua
BioFlorida held its Celebration of Biotechnology today behind the new AGTC buildings on US Hwy 441 in Alachua, just across from Progress Park, highlighting the future plans for the area that will be known as the Progress District. The Celebration was the first since 2019.
RTI Surgical Is Growing Its Footprint in Progress Park as the Biotech Industry Continues To Develop in Alachua
The biotech industry is expanding in Alachua, and companies are moving to North Central Florida from across the country. Mayor Gib Coerper of the City of Alachua said the growth in the life sciences industry is on a roll across the city.
Florida Institute and MPWRM Resource Center Fund Amend Surgical
UF Innovate | Sid Martin Biotech alum Amend Surgical, Inc., an Alachua-based medical device company, announced that it has finalized a funding agreement with the Institute for Commercialization of Florida Technology (the Florida Institute) along with being awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center.
Entrinsic Bioscience Steps Closer to Amino Acid Formulation as Therapy for Cystic Fibrosis
Entrinsic Bioscience and its licensee Nuvara Therapeutics announce they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations
Entrinsic Bioscience Announces Tool with Potential for Development of New Therapies Addressing Constipation
Entrinsic Bioscience announces a tool to measure intestinal peristalsis that could lead to the development of therapeutic agents for constipation, including Irritable Bowel Syndrome-Constipation (IBS-C).
Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
